Join Prof. Matthew Johnson, PhD, Professor of Psychiatry and Behavioral Sciences at Johns Hopkins School of Medicine as he explores how psychedelics may be leveraged in the treatment of a variety of nominally distinct psychiatric disorders.

Psychedelics have been used for millennia in both spiritual and medicinal contexts. Recently, a number of clinical successes with psychedelics have generated considerable excitement; nevertheless, mechanisms underlying their therapeutic efficacy are largely unknown.

In this webinar, we will summarise the current literature on non-invasive VNS in Parkinson’s disease and discuss preliminary findings of its therapeutic potential with an emphasis on its efficacy in improving cognitive and gait control in people with Parkinson’s.

In this session, Pall Corporation and Evello International will share their best practices on how to optimize your extraction and filtration process.

In this presentation, Cosmo Feilding-Mellen, co-founder and chief executive of Oxford-based psychedelic medicine company Beckley Psytech will take stock of the current psychedelic innovation landscape and the vast potential for psychedelic treatments in healthcare.

A team has set out to study the interactions between astrocytes and neurons, hoping to better comprehend the functional roles of astrocytes in a range of neurodegenerative diseases.

Our December 3 online event, The Origin of Neurodegeneration, will feature an expert panel who will review innovative research that could lead to a deeper understanding of the basics of nerve cell function and failure. Register now to submit a question to our panel.

During this webinar, we will discuss our hiPSC-derived cortical and sensory neurons, co-culture and their electrophysiological characterization using microelectrode arrays (MEA). The focus is on the development of disease models, co-culture, pharmacology and neurotoxicity screening.

During this webinar, we will discuss our hiPSC-derived cardiomyocytes and a custom service we provide for their electrophysiological characterization using microelectrode arrays (MEA). The focus is on the development of disease models and cardiotoxicity screening.

Watch this webinar to find out more about models designed for cell-to-cell interactions and fragment-based libraries.